• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000597.SZ
Share

Northeast Pharmaceutical Group Co., Ltd. Stocks

CN¥ 4.7Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 949.74M

CN¥ 4.7
Key Takeaways

Risk factor

Modest price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Northeast Pharmaceutical Group Co., Ltd., established in 1993 and headquartered in Shenyang, China, is a key manufacturer and supplier of active pharmaceutical ingredients (APIs) derived from both chemical synthesis and bio-fermentation. The company also develops and distributes various medicinal and micro-ecological preparation products within China. Its broad portfolio includes nutritional supplements such as Vitamin C and L-Carnitine, as well as specific APIs like fosfomycin and anti-AIDS compounds. Furthermore, it produces chemical goods, including pharmaceutical intermediates and chiral separation reagents. Beyond these, Northeast Pharmaceutical manufactures finished drugs for diverse applications, including digestives, narcotic medicines, and treatments for cardiovascular and cerebrovascular conditions. The group also maintains a significant presence in the medical distribution sector.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 12:20

DeepSeek Founder Is Now the Richest AI Model Developer — Bloomberg

14.07.2026 11:10

Oil prices soared to a one-month high following new attacks by the U.S. and Iran in the Strait of Hormuz

14.07.2026 10:44

Intraday volatility: SK Hynix shares rebounded after a 9% plunge

14.07.2026 10:38

Morning Highlights: Oil Prices Rise Amid Strikes on Iran; Nvidia Tightens Export Controls

14.07.2026 09:30

Sam Altman "took the scam to a whole new level": Musk comments on Apple's lawsuit against OpenAI

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026